Waverley Pharma Inc.
WAVE.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 803.91% | -77.09% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 803.91% | -77.09% | -- | -- |
| Cost of Revenue | -- | 152.58% | -89.31% | -- | -- |
| Gross Profit | -- | 496.94% | -41.85% | -- | -- |
| SG&A Expenses | -5.62% | -18.74% | -71.14% | -50.45% | -40.88% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 71.03% | 8.32% | -34.51% | -20.23% | -49.01% |
| Operating Income | 91.82% | 77.76% | 20.02% | -32.22% | 30.40% |
| Income Before Tax | 87.19% | 95.25% | 13.41% | -40.47% | 21.95% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 87.19% | 95.25% | 13.41% | -40.47% | 21.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 87.19% | 95.25% | 13.41% | -40.47% | 21.95% |
| EBIT | 91.82% | 77.76% | 20.02% | -32.22% | 30.40% |
| EBITDA | 101.11% | 76.49% | -11.48% | -51.06% | 40.50% |
| EPS Basic | 86.11% | 95.05% | 13.95% | -42.42% | 21.74% |
| Normalized Basic EPS | 86.96% | 84.85% | 14.81% | -38.10% | 20.69% |
| EPS Diluted | 86.11% | 95.05% | 2.67% | -121.21% | 51.35% |
| Normalized Diluted EPS | 86.96% | 84.85% | 14.81% | -38.10% | 20.69% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |